S100B and neoplasm: As a consequence, neural progenitor markers (for example, Nestin) and astrocyte lineage markers (for example, S100B and GFAP) are widely used to characterize patient tumors19,21,22,24,37–39, with Nestin+ GSCs representing a treatment-resistant subpopulation that sustains long-term tumor growth9–11,16.